385 related articles for article (PubMed ID: 25056464)
1. Assessment of sub-endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study.
Ghosh S; Chattopadhyay R; Goswami S; Chaudhury K; Chakravarty B; Ganesh A
J Obstet Gynaecol Res; 2014 Jul; 40(7):1871-6. PubMed ID: 25056464
[TBL] [Abstract][Full Text] [Related]
2. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone.
Czajkowski K; Sienko J; Mogilinski M; Bros M; Szczecina R; Czajkowska A
Fertil Steril; 2007 Mar; 87(3):613-8. PubMed ID: 17126337
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of dydrogesterone and micronized progesterone for luteal phase support during in vitro fertilization (IVF) cycles.
Saharkhiz N; Zamaniyan M; Salehpour S; Zadehmodarres S; Hoseini S; Cheraghi L; Seif S; Baheiraei N
Gynecol Endocrinol; 2016; 32(3):213-7. PubMed ID: 26486011
[TBL] [Abstract][Full Text] [Related]
4. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization.
Tournaye H; Sukhikh GT; Kahler E; Griesinger G
Hum Reprod; 2017 May; 32(5):1019-1027. PubMed ID: 28333318
[TBL] [Abstract][Full Text] [Related]
5. Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial.
Tomic V; Tomic J; Klaic DZ; Kasum M; Kuna K
Eur J Obstet Gynecol Reprod Biol; 2015 Mar; 186():49-53. PubMed ID: 25622239
[TBL] [Abstract][Full Text] [Related]
6. Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence.
Coomarasamy A; Devall AJ; Brosens JJ; Quenby S; Stephenson MD; Sierra S; Christiansen OB; Small R; Brewin J; Roberts TE; Dhillon-Smith R; Harb H; Noordali H; Papadopoulou A; Eapen A; Prior M; Di Renzo GC; Hinshaw K; Mol BW; Lumsden MA; Khalaf Y; Shennan A; Goddijn M; van Wely M; Al-Memar M; Bennett P; Bourne T; Rai R; Regan L; Gallos ID
Am J Obstet Gynecol; 2020 Aug; 223(2):167-176. PubMed ID: 32008730
[TBL] [Abstract][Full Text] [Related]
7. Comparison of oral dydrogesterone and vaginal micronized progesterone for luteal phase support in intrauterine insemination.
Taş M; Uludag SZ; Aygen ME; Sahin Y
Gynecol Endocrinol; 2020 Jan; 36(1):77-80. PubMed ID: 31464143
[TBL] [Abstract][Full Text] [Related]
8. Dydrogesterone use in early pregnancy.
Mirza FG; Patki A; Pexman-Fieth C
Gynecol Endocrinol; 2016; 32(2):97-106. PubMed ID: 26800266
[TBL] [Abstract][Full Text] [Related]
9. Comparison of oral dydrogestrone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study.
Ganesh A; Chakravorty N; Mukherjee R; Goswami S; Chaudhury K; Chakravarty B
Fertil Steril; 2011 May; 95(6):1961-5. PubMed ID: 21333984
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of micronised vaginal progesterone versus oral dydrogestrone in the treatment of irregular dysfunctional uterine bleeding: a pilot randomised controlled trial.
Karakus S; Kiran G; Ciralik H
Aust N Z J Obstet Gynaecol; 2009 Dec; 49(6):685-8. PubMed ID: 20070724
[TBL] [Abstract][Full Text] [Related]
11. Supplementary dydrogesterone is beneficial as luteal phase support in artificial frozen-thawed embryo transfer cycles compared to micronized progesterone alone.
Vidal A; Dhakal C; Werth N; Weiss JM; Lehnick D; Kohl Schwartz AS
Front Endocrinol (Lausanne); 2023; 14():1128564. PubMed ID: 36992810
[TBL] [Abstract][Full Text] [Related]
12. Oral dydrogesterone vs. vaginal progesterone capsules for luteal-phase support in women undergoing embryo transfer: a systematic review and meta-analysis.
Barbosa MWP; Valadares NPB; Barbosa ACP; Amaral AS; Iglesias JR; Nastri CO; Martins WP; Nakagawa HM
JBRA Assist Reprod; 2018 Jun; 22(2):148-156. PubMed ID: 29488367
[TBL] [Abstract][Full Text] [Related]
13. Oral dydrogesterone vs. micronized vaginal progesterone gel for luteal phase support in frozen-thawed single blastocyst transfer in good prognosis patients.
Ozer G; Yuksel B; Yucel Cicek OS; Kahraman S
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):102030. PubMed ID: 33271319
[TBL] [Abstract][Full Text] [Related]
14. Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone.
Patki A; Pawar VC
Gynecol Endocrinol; 2007 Oct; 23 Suppl 1():68-72. PubMed ID: 17943542
[TBL] [Abstract][Full Text] [Related]
15. Effect of oral administration of dydrogestrone versus vaginal administration of natural micronized progesterone on the secretory transformation of endometrium and luteal endocrine profile in patients with premature ovarian failure: a proof of concept.
Fatemi HM; Bourgain C; Donoso P; Blockeel C; Papanikolaou EG; Popovic-Todorovic B; Devroey P
Hum Reprod; 2007 May; 22(5):1260-3. PubMed ID: 17227809
[TBL] [Abstract][Full Text] [Related]
16. Dydrogesterone in the reduction of recurrent spontaneous abortion.
El-Zibdeh MY
J Steroid Biochem Mol Biol; 2005 Dec; 97(5):431-4. PubMed ID: 16253504
[TBL] [Abstract][Full Text] [Related]
17. Comparison of vaginal progesterone gel combined with oral dydrogesterone versus intramuscular progesterone for luteal support in hormone replacement therapy-frozen embryo transfer cycle.
Xu H; Zhang XQ; Zhu XL; Weng HN; Xu LQ; Huang L; Liu FH
J Gynecol Obstet Hum Reprod; 2021 Sep; 50(7):102110. PubMed ID: 33727207
[TBL] [Abstract][Full Text] [Related]
18. Dydrogesterone in threatened miscarriage: a Malaysian experience.
Pandian RU
Maturitas; 2009 Dec; 65 Suppl 1():S47-50. PubMed ID: 20005647
[TBL] [Abstract][Full Text] [Related]
19. Dydrogesterone support in threatened miscarriage.
El-Zibdeh MY; Yousef LT
Maturitas; 2009 Dec; 65 Suppl 1():S43-6. PubMed ID: 20007011
[TBL] [Abstract][Full Text] [Related]
20. Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis.
Griesinger G; Blockeel C; Kahler E; Pexman-Fieth C; Olofsson JI; Driessen S; Tournaye H
PLoS One; 2020; 15(11):e0241044. PubMed ID: 33147288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
